Summary
Agilent Technologies, Inc. reported total net revenue of $1,798 million for the three months ended January 31, 2026, a 7% increase year-over-year, with favorable foreign currency movements contributing 3 percentage points to this growth. Net income for the quarter was $305 million, a slight decrease from $318 million in the prior year period. While overall revenue grew, driven by increases across all segments and geographic regions, the company faced increased costs impacting gross and operating margins. Notably, higher tariffs, unfavorable business mix including the specialty CDMO business, wage increases, and restructuring costs contributed to a decrease in gross margin. Selling, general, and administrative expenses also saw a significant increase, partly due to transformation initiatives and restructuring costs. Despite these pressures, the company continues to invest in R&D and capacity expansion, particularly for nucleic acid-based therapeutics.
Financial Highlights
57 data points| Revenue | $1.80B |
| Cost of Revenue | $852.00M |
| Gross Profit | $946.00M |
| R&D Expenses | $117.00M |
| SG&A Expenses | $476.00M |
| Operating Expenses | $1.45B |
| Operating Income | $353.00M |
| Interest Expense | $25.00M |
| Net Income | $305.00M |
| EPS (Basic) | $1.08 |
| EPS (Diluted) | $1.07 |
| Shares Outstanding (Basic) | 283.00M |
| Shares Outstanding (Diluted) | 284.00M |
Key Highlights
- 1Total net revenue increased by 7% to $1,798 million for the three months ended January 31, 2026, compared to the prior year period.
- 2Net income for the quarter was $305 million, down from $318 million in the prior year.
- 3Gross margin decreased by 1 percentage point to 52.6% due to higher tariffs, unfavorable business mix, and increased costs.
- 4Operating margin decreased by 3 percentage points to 19.7% driven by increased tariffs, restructuring costs, and SG&A expenses.
- 5The company repurchased approximately $152 million of common stock under its 2024 repurchase program during the quarter.
- 6Cash provided by operating activities decreased to $268 million from $431 million in the prior year, impacted by higher tax payments and variable pay programs.
- 7Agilent expects to fully offset the impact of tariff changes on its cost of revenue during fiscal year 2026 through mitigation strategies.